<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707161</url>
  </required_header>
  <id_info>
    <org_study_id>HCI15461</org_study_id>
    <nct_id>NCT00707161</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma</brief_title>
  <official_title>A Prospective Phase II Study of Radiation Therapy and Concurrent Cisplatin Chemotherapy in the Treatment of Locally Advanced or Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective phase II trial of radiation therapy concurrent with cisplatin
      chemotherapy in the treatment of locally advanced or metastatic melanoma in patients who are
      deemed to require radiation therapy by treating physicians for purposes of local control or
      palliation. Eligibility criteria include pathologically confirmed melanoma. Patients will
      undergo radiation therapy (20 treatments of 2.5 Gy for a total of 50 Gy) concurrent with
      cisplatin chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, prospective trial designed to determine the response rate achieved with
      cisplatin delivered concurrent with radiation therapy in locally advanced or metastatic
      melanoma.

      Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in
      table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20
      treatments). Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses
      (days 1 and 22) during radiation.

      Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be
      performed following chemoradiation if deemed appropriate by the treating physicians (surgical
      resection may be planned following pre-operative chemoradiation or may be performed for
      salvage due to inadequate response to chemoradiation or for relapse following
      chemoradiation). Surgical resection will not be performed until at least 4 weeks following
      chemoradiation (unless deemed emergent by the treating physicians).

      If the patient's tumor has inadequate response to chemoradiation then salvage therapies can
      be used as deemed appropriate by the treating physicians. In order to allow adequate response
      to radiation therapy, salvage therapies will not be utilized until at least 4 weeks following
      chemoradiation unless deemed emergent by the treating physicians.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    discontinued due to low enrollment
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate of Melanoma Lesions</measure>
    <time_frame>2005-2010</time_frame>
    <description>Response rate of melanoma lesions was measured after treated with the trial agent.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed study-specific consent form prior to registration.

          -  Pathologically confirmed malignant melanoma.

          -  Measurable melanoma lesion deemed to require radiation by treating physicians for
             purposes of local control or palliation. The lesion may be the primary melanoma, a
             nodal metastasis, or a distant metastasis. Recurrent lesions are allowed.

          -  Lesion has to be measurable clinically or radiographically in 2 dimensions.

          -  Karnofsky Performance Scale (KPS) &gt; 70.

          -  Laboratory values

               -  White blood cells (WBC) &gt; 3000/mm3

               -  Absolute granulocyte count &gt; 1,500

               -  Platelets &gt; 100,000/mm3

               -  Total bilirubin &lt; 2.0 x institutional upper limit of normal

               -  AST or ALT (aminotransferase/alanine aminotransferase) &lt; 2.5 x institutional
                  upper limit of normal

               -  Serum calcium &lt; 1.3 x institutional upper limit of normal

               -  Serum creatinine &lt; 1.5 mg/dL or Creatinine clearance &gt; 50 cc/min,calculated as
                  follows: CCr = 0.85 x (140-age) x (weight in kg) 72 x serum creatinine in mg/dL

        Exclusion criteria:

          -  Systemic therapy for malignant melanoma within one month preceding trial enrollment.

          -  Prior irradiation to the planned field.

          -  Concomitant chemotherapy (in addition to cisplatin) or biologic therapy is allowed.

          -  Significant infection or other co-existent medical condition which would prevent the
             use of full dose chemotherapy.

          -  Pre-existing sensory neuropathy (CTC 3.0 â‰¥ Grade II)

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Shrieve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2008</study_first_posted>
  <results_first_submitted>April 20, 2011</results_first_submitted>
  <results_first_submitted_qc>March 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2012</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm (Radiation Therapy &amp; Cisplatin)</title>
          <description>All patients will receive Radiation Therapy and Cisplatin for their melanoma. If appropriate patients will have surgical resection for residual or recurrent melanoma following chemoradiation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">3 deceased (1-Huntsman Cancer Institute, 2- LDS Hospital).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm (Radiation Therapy &amp; Cisplatin)</title>
          <description>Radiation therapy given at 50 Gy, 20 fractions, for 4 weeks (2.5 Gy/day). Cisplatin given at 100mg/m2 i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate of Melanoma Lesions</title>
        <description>Response rate of melanoma lesions was measured after treated with the trial agent.</description>
        <time_frame>2005-2010</time_frame>
        <population>Study terminated. Analysis not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm (Radiation &amp; Cisplatin)</title>
            <description>Group of participants receiving Radiation and Cisplatin.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate of Melanoma Lesions</title>
          <description>Response rate of melanoma lesions was measured after treated with the trial agent.</description>
          <population>Study terminated. Analysis not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm (Radiation Therapy &amp; Cisplatin)</title>
          <description>Radiation therapy given at 50 Gy, 20 fractions, for 4 weeks (2.5 Gy/day). Cisplatin given at 100mg/m2 i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to low enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dennis Shrieve, MD</name_or_title>
      <organization>Huntsman Cancer Institute</organization>
      <phone>801-581-8793</phone>
      <email>dennis.shrieve@hci.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

